INO

INOVIO PHARMACEUTICALS, INC. - 10-Q Summary (Q2 2025)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and proprietary CELLECTRA delivery devices for HPV-associated diseases, cancer, and infectious diseases. The company's lead candidate, INO-3107, targets recurrent respiratory papillomatosis (RRP). As of the filing date, the company has not generated material revenue from product sales and relies on financing, grants, and collaboration agreements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the three months ended June 30, 2025, compared to $100,762 in the same period in 2024. For the six months, revenue was $65,343 versus $100,762 in 2024. All revenue is derived from the ApolloBio collaboration.
• Net Loss: Net loss decreased to $(23.52) million for the quarter (from $(32.24) million in Q2 2024) and $(43.21) million for the six months (from $(62.71) million in the prior year period). This improvement is primarily due to reduced operating expenses.
• Operating Expenses: Total operating expenses decreased by 31% year-over-year for the quarter ($23.1 million vs. $33.3 million) and 26% for the six months ($48.2 million vs. $64.8 million).
  • R&D Expenses: Decreased significantly, driven by lower drug manufacturing and clinical study costs for INO-3107 and reduced stock-based compensation.
  • G&A Expenses: Decreased due to lower severance, stock-based compensation, and legal expenses.
• Investment Gains: The company recorded a gain of $776,373 on its investment in affiliated entity (Plumbline Life Sciences) for the quarter, compared to a loss of $(334,294) in the prior year.
• Warrant Liability: A loss of $(1.88) million was recorded for the quarter due to the change in fair value of the common stock warrant liability, whereas no such liability existed in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2026. Current cash resources, combined with proceeds from a subsequent July 2025 offering, are expected to fund operations only until that date.
• Recent Financing: On July 7, 2025 (subsequent to the period end), the company closed an underwritten public offering raising net proceeds of $22.5 million.
• Regulatory Outlook: The company requested a rolling submission of its Biologic License Application (BLA) for INO-3107 in July 2025, aiming for FDA file acceptance by the end of 2025. A manufacturing issue with the CELLECTRA device was resolved in Q1 2025.
• Litigation: On August 1, 2025, the company entered into a Settlement Agreement with GeneOne Life Science, Inc. to settle all claims between the parties. Litigation with VGXI remains ongoing with no trial date set.
• Risks: Key risks include the need for substantial additional capital, failure to obtain FDA approval for drug-device combination products, reliance on third-party manufacturers, and potential dilution from future equity financings.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $47.5 million cash balance plus the $22.5 million July 2025 proceeds to fund operations through Q2 2026, given the high burn rate.
• INO-3107 BLA Status: Confirm the timeline for the rolling BLA submission and the FDA's acceptance of the application, as this is the primary path to revenue.
• Manufacturing Capacity: Assess the stability of the supply chain for the CELLECTRA device and DNA plasmids following the previously reported manufacturing issues.
• Dilution Risk: Monitor future financing activities, as the company explicitly states it will need additional capital to commercialize products, likely through dilutive equity offerings.
• Litigation Resolution: Review the terms of the GeneOne settlement and the status of the VGXI litigation to understand potential financial liabilities.